Conditions: Helicobacter Pylori Infection
Keywords: bacterial infections anti-infective agents gastrointestinal agents antibacterial agents omeprazole lauric acid n-acetylcysteine helicobacter infections helicobacter pylori non-antibiotic treatment
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 33
Healthy volunteers: yes

Brief summary:
At present, triple therapy is recommended by various guidelines for the treatment of Helicobacter pylori (H.pylori) infection. Recent studies have shown increasing resistance of H.pylori to commonly used antibiotics used in triple therapy. This study explores a non-antibiotic treatment regime for H.pylori that uses lauric acid as the primary anti-microbial agent. The study hypothesis is that Lauric acid works synergistically with omeprazole following administration of a mucolytic agent to kill H.pylori topically in the stomach.

Detailed description:

Arms:
arm 1: Initial phase - omeprazole, N-acetyl cysteine (NAC), lauric acid dose and duration titration from 1 up to 14 days of treatment. Secondary phase - 14 days treatment with omeprazole, NAC, lauric acid

Interventions: intervention 1: GT08
Intervention descriptions: intervention 1: GT08 is the combination of omeprazole 40mg daily, lauric acid 150-300mg daily, NAC 1.2 - 2g daily

Protocol document: